Skip to main content

Table 1 Patient characteristics

From: Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients

Age at baseline (median with range)

67 (35–83)

Gender (% females)

36/66 (55%)

Prior systemic therapy:

 None

36

 IL-2

12

 Temozolomide

6

 Radiation therapy/IL-2

1

 Radiation therapy

1

 Temozolomide/Vemorafenib

1

 RT/Temozolomide

1

 IFN/IL-2

6

 Vemorafenib

2

RECIST response

 PD

41

 SD

14

 PR

9

 CR

2

Lactate dehydrogenase (LDH)

 > = 250 IU/L

12

 < 250 IU/L

53

  1. PD Progressive disease, SD Stable disease, PR Partial response, CR Complete response
Back to article page